 |
|
|
|
|
Current
Trials
Validated Technology
Argos’ RNA-loaded dendritic cell immunotherapy has been validated
in numerous preclinical studies of tumor metastasis in animals as well
as in clinical trials in humans. In the clinical trials, the immunotherapy
was well tolerated, induced a potent anti-tumor response and demonstrated
encouraging clinical responses.
Therapeutic Areas
Metastatic Renal Cell Carcinoma (RCC)
Argos
has completed an initial Phase 1/2 study of its total tumor RNA-loaded
dendritic cell (DC) immunotherapy in RCC. The trial successfully demonstrated
that the immunotherapy was well-tolerated (no drug related serious adverse
events) and the commercial feasibility of processing the product at a
central manufacturing facility with delivery to multiple clinical sites.
In addition, disease progression and overall median survival data from
the trial were encouraging.
A second Phase 1/2 study that replicates the protocol of the prior study
and employs an enhanced proprietary process is currently enrolling and
treating patients.
For further information and eligibility criteria, refer
to the National Institutes of Health ClinicalTrials.gov Web site at http://www.clinicaltrials.gov/ct/show/NCT00272649?order=1
Chronic Lymphocytic Leukemia (CLL)
Applying the same enhanced process used in its current RCC trial, Argos
developed an RNA-loaded DC immunotherapy to treat CLL. Graeme Fraser,
M.D., is conducting an investigator-sponsored Phase 1/2 study with
Argos’ personalized immunotherapeutic at McMaster University
in Hamilton, Ontario, Canada.
Human Immunodeficiency Virus (HIV)
An investigator-sponsored Phase 1 trial measuring safety and immunogenicity
is being conducted at McGill University Health Center in Montreal under
the direction of Jean-Pierre Routy, M.D., associate professor and principal
clinical investigator of the Division of Hematology and Immunodeficiency
Service. The novel Argos RNA-loaded DC therapy for HIV utilizes small
plasma samples from infected patients to amplify large quantities of
viral RNA encoding selected antigens, resulting in a personalized treatment
to the patient’s own strain of virus. A larger HIV trial is scheduled
to begin in 2007 , and, in addition to safety, will measure efficacy
in terms of viral load control. For further information see the following site at http://www.clinicaltrials.gov/ct/show/NCT00381212?order=2
CLINICAL PIPELINE
| Description |
Indication |
Status |
| AGS-003 |
Metastatic Renal Cell Carcinoma |
Ph 1/2 |
| AGS-005 |
Chronic Lymphocytic Leukemia |
Ph 1/2 |
| AGS-004 |
HIV |
Ph 1 |
|
|
|
 |
|
